Clinton A. Jr. Lewis Sells 6,125 Shares of Zoetis Inc (ZTS) Stock

Zoetis Inc (NYSE:ZTS) insider Clinton A. Jr. Lewis sold 6,125 shares of the firm’s stock in a transaction that occurred on Thursday, February 14th. The shares were sold at an average price of $91.96, for a total value of $563,255.00. Following the completion of the sale, the insider now directly owns 45,512 shares in the company, valued at $4,185,283.52. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Shares of NYSE:ZTS traded up $2.11 during trading on Friday, reaching $95.37. The stock had a trading volume of 3,291,621 shares, compared to its average volume of 2,661,516. The company has a debt-to-equity ratio of 3.04, a current ratio of 4.06 and a quick ratio of 2.63. The firm has a market capitalization of $44.81 billion, a PE ratio of 39.74, a P/E/G ratio of 1.62 and a beta of 0.88. Zoetis Inc has a 1-year low of $77.00 and a 1-year high of $96.57.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Thursday, February 14th. The company reported $0.79 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.77 by $0.02. The firm had revenue of $1.56 billion for the quarter, compared to analyst estimates of $1.53 billion. Zoetis had a return on equity of 75.51% and a net margin of 20.35%. The business’s revenue was up 7.1% on a year-over-year basis. During the same period in the previous year, the company posted $0.69 earnings per share. As a group, analysts expect that Zoetis Inc will post 3.11 earnings per share for the current year.

The company also recently declared a quarterly dividend, which will be paid on Monday, June 3rd. Stockholders of record on Thursday, April 18th will be paid a $0.164 dividend. This represents a $0.66 dividend on an annualized basis and a dividend yield of 0.69%. The ex-dividend date of this dividend is Wednesday, April 17th. Zoetis’s dividend payout ratio is presently 27.50%.

Zoetis announced that its Board of Directors has initiated a share buyback program on Wednesday, December 12th that permits the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization permits the company to purchase up to 4.7% of its shares through open market purchases. Shares repurchase programs are usually a sign that the company’s board of directors believes its stock is undervalued.

Several analysts have commented on the company. Zacks Investment Research lowered Zoetis from a “hold” rating to a “sell” rating in a report on Monday, February 4th. Argus set a $105.00 price objective on Zoetis and gave the company a “buy” rating in a report on Tuesday, November 13th. BMO Capital Markets reissued a “hold” rating on shares of Zoetis in a report on Sunday, November 11th. JPMorgan Chase & Co. raised their price objective on Zoetis from $100.00 to $101.00 and gave the company an “overweight” rating in a report on Friday, November 2nd. Finally, UBS Group assumed coverage on Zoetis in a report on Wednesday, January 23rd. They issued a “neutral” rating and a $86.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and eleven have issued a buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $93.53.

Large investors have recently modified their holdings of the company. Berman Capital Advisors LLC acquired a new stake in shares of Zoetis in the fourth quarter worth approximately $26,000. Athena Capital Advisors LLC acquired a new stake in shares of Zoetis in the fourth quarter worth approximately $29,000. Resources Investment Advisors Inc. acquired a new stake in shares of Zoetis in the fourth quarter worth approximately $31,000. Lavaca Capital LLC acquired a new position in Zoetis during the fourth quarter worth $32,000. Finally, Acima Private Wealth LLC acquired a new position in Zoetis during the fourth quarter worth $34,000. 92.87% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: This piece was published by WKRB News and is the sole property of of WKRB News. If you are accessing this piece on another publication, it was illegally stolen and reposted in violation of US & international copyright and trademark legislation. The correct version of this piece can be read at

About Zoetis

Zoetis Inc discovers, develops, manufactures, and markets veterinary vaccines and medicines in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.

Recommended Story: Understanding Market Liquidity

Insider Buying and Selling by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with's FREE daily email newsletter.